{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-036278","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.582183+00:00","generated_at":"2026-05-25T02:34:18.861120+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lineage Cell narrows Q4 net loss to $3.3M; OpRegen gets FDA RMAT designation","bullets":["Net loss of $3.3M ($0.02/shr) for Q4 2024 vs $4.8M ($0.03/shr) in Q4 2023; revenue $2.9M vs $2.1M.","Cash of $47.8M at Dec 31, 2024 plus $5.5M from Jan 2025 close; funds operations into Q1 2027.","OpRegen (dry AMD/GA) received FDA RMAT designation; positive 24-month visual acuity data reported.","OPC1 DOSED study initiated Feb 2025 in spinal cord injury; UC San Diego Health first site.","Closed financings for $44M gross proceeds; potential $36M from milestone-linked warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-036278","json":"https://secwatch.observer/filing/0000950170-25-036278.json","markdown":"https://secwatch.observer/filing/0000950170-25-036278.md","text":"https://secwatch.observer/filing/0000950170-25-036278.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000095017025036278/0000950170-25-036278-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000095017025036278/lctx-20250310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T02:34:18.861120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}